Biotech RadarJobs updated

COMPANY

Tanabe Pharma America

HQ: Jersey City, NJ (US office) source · us.tanabe-pharma.com ↗

Status: Acquired, now part of Tanabe · How status works

Clinical Phase 3

Location: Jersey City, NJ (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Erythropoietic Protoporphyria Spinal Cord Injury X-Linked Protoporphyria Menopause Hot Flashes Vasomotor Symptoms Endometrial Related Pain Diffuse Cutaneous Systemic Sclerosis Head and Neck Squamous Cell Carcinoma Non-small Cell Lung Cancer Esophageal Cancer Gastric Cancer Biliary Tract Cancer Pancreatic Ductal Adenocarcinoma Breast Cancer Ovarian Cancer Cervical Cancer Endometrial Cancer Prostate Cancer Urothelial Carcinoma Neuroendocrine Tumor Neuroendocrine Carcinoma Soft Tissue Sarcoma Nuclear Protein in Testis (NUT) Carcinoma Renal Impairment Normal Renal Function Mild and Moderate Hepatic Impairment MT-7117 Dersimelagon MT-8554 MT-6345 MT-2990

20Trials (company is sponsor)

Timeline

  1. Trial start Phase 1/Phase 2: A Study of MT-4561 in Patients With Various Advanced Solid Tumors source ↗
  2. Trial start Phase 3: INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP source ↗
  3. Trial start Phase 1: Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects source ↗
  4. Trial start Phase 2: Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury source ↗
  5. Trial start Phase 3: Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) source ↗
  6. Trial start Phase 1: Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects source ↗
  7. Trial start Phase 2: Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis source ↗
  8. Trial start Phase 1: PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function source ↗
  9. Trial start Phase 3: Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria source ↗
  10. Trial start Phase 1: Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury source ↗
  11. Trial start Phase 1: Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function source ↗
  12. Trial start Phase 1: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects source ↗
  13. Trial start Phase 2: Safety and Efficacy Study of MT-2990 in Women With Endometriosis source ↗
  14. Trial start Phase 1: Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor source ↗
  15. Trial start Phase 2: Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria source ↗
  16. Trial start Phase 1: Definitive QT Study With MT-8554 source ↗
  17. Trial start Phase 2: Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms source ↗
  18. Trial start Phase 1: Mass Balance Study With MT-7117 source ↗
  19. Trial start Phase 1: Mass Balance Study With MT-8554 source ↗
  20. Trial start Phase 2: MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 20

RecordTitlePhaseStatusStartPrimary completion
NCT05005975Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)Phase 3Active, not recruitingAug 10, 20212027-12 (estimated)
NCT06144840INcreased Sun Exposure Without Pain In Research Participants With EPP or XLPPhase 3CompletedDec 11, 2023Apr 14, 2026 (actual)
NCT03291067MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal WomenPhase 2CompletedOct 9, 2017Oct 19, 2018 (actual)
NCT03541200Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor SymptomsPhase 2CompletedApr 18, 2018Nov 15, 2019 (actual)
NCT03809039A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy SubjectsPhase 1TerminatedJan 15, 2019Jul 1, 2019 (actual)
NCT03840993Safety and Efficacy Study of MT-2990 in Women With EndometriosisPhase 2CompletedJan 15, 2019May 13, 2021 (actual)
NCT03520036Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic ProtoporphyriaPhase 2CompletedJul 5, 2018Sep 28, 2019 (actual)
NCT04440592Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic SclerosisPhase 2CompletedFeb 5, 2021Jan 17, 2024 (actual)
NCT04402489Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked ProtoporphyriaPhase 3CompletedJun 1, 2020Dec 14, 2021 (actual)
NCT03381404Mass Balance Study With MT-8554Phase 1CompletedDec 19, 2017Jan 29, 2018 (actual)
NCT03471130Definitive QT Study With MT-8554Phase 1CompletedApr 23, 2018Oct 19, 2018 (actual)
NCT04683848Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord InjuryPhase 2CompletedAug 27, 2021Dec 24, 2024 (actual)
NCT06943521A Study of MT-4561 in Patients With Various Advanced Solid TumorsPhase 1/Phase 2RecruitingApr 18, 20252028-08 (estimated)
NCT03503266Mass Balance Study With MT-7117Phase 1CompletedMar 23, 2018May 11, 2018 (actual)
NCT04656795PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal FunctionPhase 1CompletedDec 2, 2020Dec 4, 2021 (actual)
NCT03688022Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump InhibitorPhase 1CompletedOct 25, 2018Dec 22, 2018 (actual)
NCT04793295Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy SubjectsPhase 1CompletedMar 23, 2021Feb 4, 2022 (actual)
NCT04096950Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord InjuryPhase 1CompletedApr 19, 2020Jan 6, 2021 (actual)
NCT05241535Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy SubjectsPhase 1CompletedJan 12, 2022Feb 23, 2022 (actual)
NCT04116476Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic FunctionPhase 1CompletedAug 1, 2019Feb 16, 2021 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback